Stock YP1A IMMUTEP ADR
Add to a list
To use this feature you must be a member
Log inSign up

Ratings Immutep ADR Deutsche Boerse AG

Equities

YP1A

US45257L1089

Delayed Deutsche Boerse AG
Other stock markets
 02:16:58 2024-06-03 EDT 		5-day change 1st Jan Change
2.66 EUR +3.91% Intraday chart for Immutep ADR +3.10% +25.47%
10:57am Immutep, Merck Collaborate on Trial for Lung Cancer Therapy MT
07:20am Immutep, Merck Partner for Efti and Keytruda Combo in Lung Cancer Trial MT

Summary

  • From a short-term investment perspective, the company presents a deteriorated fundamental situation

Strengths

  • According to sales estimates from analysts polled by Standard & Poor's, the company is among the best with regard to growth.
  • Thanks to a sound financial situation, the firm has significant leeway for investment.
  • Analysts covering this company mostly recommend stock overweighting or purchase.
  • The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
  • The group usually releases upbeat results with huge surprise rates.

Weaknesses

  • As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
  • The company has insufficient levels of profitability.
  • Based on current prices, the company has particularly high valuation levels.
  • The company appears highly valued given the size of its balance sheet.
  • For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
  • The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
  • For the past year, analysts have significantly revised downwards their profit estimates.
  • For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
  • Over the past four months, analysts' average price target has been revised downwards significantly.
  • Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

1st Jan change Capi. Investor Rating ESG Refinitiv
IMMUTEP ADR Stock Immutep ADR
+25.47% 355M -
MODERNA, INC. Stock Moderna, Inc.
+50.14% 54.63B
B-
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
-4.84% 39.92B
B
LONZA GROUP AG Stock Lonza Group AG
+37.18% 38.82B
A
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+15.67% 26.86B
B-
CELLTRION, INC. Stock Celltrion, Inc.
-12.56% 26.22B
C
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-21.59% 18.78B
B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+25.59% 12.21B
B+
BIO-TECHNE CORPORATION Stock Bio-Techne Corporation
+1.88% 12.16B
B+
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+26.93% 11.94B
C+
Investor Rating
Trading Rating
ESG Refinitiv
-

Financials

Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances

Valuation

P/E ratio
-
EV / Sales
Price to Book
Price to Free Cash Flow
-
Yield
-

Momentum

1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision

Consensus

Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion

Business Predictability

Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality

Technical analysis

ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
  1. Stock Market
  2. Equities
  3. IMM Stock
  4. YP1A Stock
  5. Ratings Immutep ADR